Cellectar Biosciences, Inc. Operating Income Loss

• Cellectar Biosciences, Inc. showed an increase of +55.6% in Operating Income Loss from 2024 to 2025.
• This data is from Cellectar Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 4, 2026.
• XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 16 years of available data (2010 to 2025), Cellectar Biosciences, Inc.'s Operating Income Loss has declined by 448.0%.
• Historical annual values: Fiscal year 2025: -$22.98 million | Fiscal year 2024: -$51.78 million | Fiscal year 2023: -$38.96 million | Fiscal year 2022: -$28.81 million | Fiscal year 2021: -$24.13 million | Fiscal year 2020: -$15.29 million | Fiscal year 2019: -$14.18 million | Fiscal year 2018: -$13.33 million | Fiscal year 2017: -$13.60 million | Fiscal year 2016: -$9.45 million | Fiscal year 2015: -$8.76 million | Fiscal year 2014: -$9.89 million | Fiscal year 2013: -$12.40 million | Fiscal year 2012: -$8.75 million | Fiscal year 2011: -$7.04 million | Fiscal year 2010: -$4.19 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026